Cullinan Associates Inc. Sells 3,357 Shares of AbbVie Inc. $ABBV

Cullinan Associates Inc. lessened its stake in AbbVie Inc. (NYSE:ABBV) by 3.8% in the third quarter, Holdings Channel.com reports. The institutional investor owned 84,786 shares of the company’s stock after selling 3,357 shares during the quarter. AbbVie makes up approximately 1.3% of Cullinan Associates Inc.’s portfolio, making the stock its 21st biggest position. Cullinan Associates Inc.’s holdings in AbbVie were worth $19,631,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in the stock. Norges Bank purchased a new position in shares of AbbVie during the 2nd quarter valued at about $4,288,200,000. Laurel Wealth Advisors LLC raised its stake in shares of AbbVie by 18,384.4% during the second quarter. Laurel Wealth Advisors LLC now owns 5,705,964 shares of the company’s stock worth $1,059,141,000 after acquiring an additional 5,675,095 shares in the last quarter. Assenagon Asset Management S.A. lifted its holdings in shares of AbbVie by 550.9% in the 2nd quarter. Assenagon Asset Management S.A. now owns 4,332,054 shares of the company’s stock worth $804,116,000 after acquiring an additional 3,666,521 shares during the last quarter. Vanguard Group Inc. boosted its stake in shares of AbbVie by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 177,298,707 shares of the company’s stock valued at $32,910,186,000 after purchasing an additional 3,380,842 shares in the last quarter. Finally, Kingstone Capital Partners Texas LLC bought a new position in shares of AbbVie during the 2nd quarter valued at $581,817,000. 70.23% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

ABBV has been the subject of several recent research reports. Guggenheim boosted their price target on shares of AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a research note on Monday, October 20th. Hsbc Global Res raised AbbVie from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, December 10th. HSBC upgraded AbbVie from a “hold” rating to a “buy” rating and raised their price target for the stock from $225.00 to $265.00 in a research report on Wednesday, December 10th. Raymond James Financial set a $256.00 price target on AbbVie in a research note on Monday, November 3rd. Finally, Wall Street Zen lowered AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Saturday, January 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $246.89.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie struck a three‑year drug‑pricing agreement with the White House that grants exemptions from certain tariffs and future pricing mandates in exchange for lower Medicaid pricing and a pledge to invest $100 billion in U.S. R&D and capital over the next decade — market sees tariff relief and large domestic investment as net positives for cash flow visibility and political risk reduction. AbbVie inks latest White House drug pricing deal, scoring tariff reprieve as it makes $100B US investment pledge
• Positive Sentiment: AbbVie agreed to an exclusive global licensing/partnering deal for RC148 (a PD‑1/VEGF bispecific) with RemeGen — up to ~$5.6B — boosting its oncology pipeline and giving upside to future sales if the asset progresses. AbbVie pens $5.6B pact with RemeGen to join PD-1xVEGF bispecific battle
• Positive Sentiment: Operational and manufacturing expansion: AbbVie is acquiring an Arizona drug‑delivery/manufacturing facility and the SmartDose on‑body system rights from West Pharma, and announced a $175M investment in an Arizona drug‑device plant — these moves support supply security, onshoring and next‑gen product delivery capacity. AbbVie to Acquire Drug Delivery System, Arizona Manufacturing Facility from West Pharma
• Neutral Sentiment: Regulatory engagement: AbbVie (with peers) is leading calls for the FDA to update post‑approval change rules — potential long‑run operational implications, but not an immediate earnings driver. AbbVie, Amgen, Lilly Lead Calls for FDA To Update Post-Approval Change Rules
• Neutral Sentiment: Clinical pipeline progress: Phase‑2 readout/trial completion for ABBV‑932 (bipolar depression) was reported — positive for pipeline optionality but early stage and uncertain commercial timing. AbbVie’s ABBV-932 Bipolar Depression Trial Reaches Completion
• Neutral Sentiment: Analyst / retail attention: Several bullish analyst pieces and increased investor searches highlight AbbVie’s dividend and value characteristics — supportive sentiment but not a direct fundamental change. Why AbbVie (ABBV) is a Top Value Stock for the Long-Term
• Negative Sentiment: Revenue and margin risk from price concessions: the White House pact requires lower Medicaid pricing and expanded affordable patient offerings, which could blunt near‑term revenue/margin growth for products used widely in public programs — investors will watch guidance and product‑level impact. Abbvie, US reach agreement to cut drug prices

AbbVie Price Performance

ABBV opened at $220.51 on Wednesday. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The business has a 50 day simple moving average of $226.84 and a two-hundred day simple moving average of $216.04. The firm has a market capitalization of $389.72 billion, a price-to-earnings ratio of 167.05, a PEG ratio of 0.92 and a beta of 0.36.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share for the quarter, beating the consensus estimate of $1.77 by $0.09. The company had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The firm’s revenue was up 9.1% on a year-over-year basis. During the same period in the previous year, the company posted $3.00 earnings per share. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. As a group, sell-side analysts expect that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, February 17th. Investors of record on Friday, January 16th will be given a dividend of $1.73 per share. This is a boost from AbbVie’s previous quarterly dividend of $1.64. The ex-dividend date of this dividend is Friday, January 16th. This represents a $6.92 dividend on an annualized basis and a yield of 3.1%. AbbVie’s dividend payout ratio is 496.97%.

AbbVie Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.